摘要
目的探讨参芪扶正注射液联合多西他赛治疗乳腺癌的临床疗效。方法将68例乳腺癌患者利用随机数字表法分为2组,各34例。对照组采用多西他赛治疗,研究组在此基础上联用参芪扶正注射液。对2组患者血清肿瘤标志物、不良反应发生情况及临床疗效进行观察对比。结果治疗前,2组患者血清中CEA、CA125和CA153水平差异不明显(P> 0. 05),但治疗后,2组较治疗前均改善显著(P <0. 05),且研究组与对照组比较,下降更为显著(P <0. 05)。经过治疗后,研究组患者的有效率及临床受益率显著优于对照组(P <0. 05)。2组患者不良反应发生率比较,差异有统计学意义(P <0. 05),且研究组不良反应程度明显低于对照组(P <0. 05)。结论参芪扶正注射液联合多西他赛治疗乳腺癌可有效减少肿瘤标志物分泌,抑制肿瘤生长,疗效显著,且不良反应率低,程度低,是一种安全有效的治疗新方案,值得推广运用。
Objective To explore and study the clinical efficacy of Shenqi Fuzheng Injection Combined with docetaxel in the treatment of breast cancer.Methods 68 cases of breast cancer patients in our hospital were selected as the research object(December 2015~2016 October).They were divided into two groups by random number table,34 cases in each group.The control group was treated with docetaxel treatment,study group of the basis of Shenqifuzheng injection.The serum tumor markers,adverse reactions and clinical effects were observed and compared in the two groups.Results Two groups of patients with serum CEA,CA125 and CA153 index before treatment were statistically no significant difference(P>0.05),but after treatment,compared with before treatment were significantly improved(P<0.05)group,and the study group decreased significantly(P<0.05);after treatment,the study group of patients the efficiency and clinical benefit rate was significantly better than the control group(P<0.05);two groups of patients with adverse reaction rate comparison,a statistically significant difference(P<0.05),and the degree of adverse reactions was significantly lower than the control group(P<0.05).Conclusion Shenqi Fuzheng Injection Combined with docetaxel in the treatment of breast cancer can effectively reduce the secretion of tumor markers,inhibit tumor growth,and has a significant effect,with a low adverse reaction rate and a low degree.It is a safe and effective new treatment plan,and is worthy of popularization and application.
作者
李成蓉
刘洋
LI Chengrong;LIU Yang(No.154 PLA Central Hospital,Xinyang,464000)
出处
《实用癌症杂志》
2018年第12期1960-1962,1966,共4页
The Practical Journal of Cancer
